Argent Biopharma Share Discussion Threads

[asmodeus] 16/7/2011 11:46

"asmodeus - 14 Jul'11 - 08:09 - 57818 of 57837

Excellent find, S_S. I have forwarded it to Tim for you.

share_shark - 14 Jul'11 - 08:11 - 57819 of 57837

You really are a ANGEL asmodeus and thank you."

[share_shark] 16/7/2011 10:04

Warning over buying Alzheimer's drugs online





I hope SK dont see this and with their wishes for their Shopping Channel.

[share_shark] 16/7/2011 09:33

asmodeus.

I have always had Tim's email addy and it was a tongue in cheek request to you for it,since you always seem to be happy to give someone or other a kick up the posterior for one reason or another.

Feel free to send on anything to Tim that you see fit . I will not and do not bother him ,either way.

For goodness sake, this is a free BB;if you do not like what is posted learn to filter a poster you dislike the modus (or spelling of).

As with regards to your comments Doc. Thank you for posting yoour thoughts concern your meeting with Tim but as with regards to your comments regarding my posting,you might wish to forget that ALWAYS ,we shareholders were guided by the company's "guidence" well Percy Lomax,in fact providing us with "profitabilty,China,S Korea,coming on stream" and all that nonsense. Who was I to question him(which I did many times). You stated you only have a small holding, well at one stage I was the second largest holder,having put my money where my mouth was and having taken part in many placings,supporting the company directly.You too might wish to use the filter button and stop behaving as if you were some sort of God,stricken with measles.

[asmodeus] 16/7/2011 08:03

Sorry S-S, but I agree with the Doctor. Now you have his address, it's important that you don't flood Tim's mailbox with long reports other than those that alert him to something upon which he might take immediate action - such as the one you found reporting relaxation of approvals by the FDA.

[the_doctor] 15/7/2011 10:10

I'll repost this:

A quick report from the RGT update meeting.

8 shareholders, plus 2 from the company.
Tim did most of the talking, as expected.
He had clear visions and put them across well.
There have been issues, but they're doing what they can to get around them. I think we're in as good a pair of hands as we could hope with Tim really.
He's realistic about the challenges and is focused on the right areas.

Norman answered the financial questions without problem and again, appears realistic.

In short, 2011 has gone well.
I got the impression that orders so far already match those in 2010 (that wasnt said specifically) and more are anticipated.

They havent used up the first £150k portion of the loan yet
Cash burn rate of £20-25k per month.

On an approx 60% margin, if they've so far got £100k from 2011 trading...
I forget how much of the filtration unit/other expenses came out of the loan?
If £35k, then for operations, there'd be £115k from the loan

So, £225k in this year would mean they'd need to draw on the second part of the loan in Oct 2011.
From then, they'll have about 5 months worth of cash.

So, we have a window until approx end March 2012
But this will be extended with any further orders.
Which in turn, will buy more time for more orders to come in.

It looks tight to me, so orders over H2 2011 and H1 2012 are ESSENTIAL

They do have a lot of things bubbling away that should lift revenue AND importantly, also margins.
Producing their own RGT tablets increases the price RGT gets by about 50%.
That would translate into a nice lift in cash flows from ex-US sales.
Add to that, input from the recent/new distribution agreements signed...


My overall view is that if they can get to 2013, then they're home and dry, as more deals kick in and the margins improve.
The critical thing IMO is getting enough cash in to cover the 5-10 months running from end of the loans to sustainability...
That will require £100-250k
Or, orders of about £170-265k
Roughly translated, they have approaching a year to bring in as many orders as they did in the last 6 months, or the same as the whole of 2010.
That'll be facilitated by margin improvement and the launch of new formulations, but really depends on how long current stocks last before re-orders come in.... that's a bit of an unknown!
Speed is of the essence.


There isnt much scope for cost cutting, but I'd hope they'd cut back even further if they really had to, such as delaying/cutting down staff pay for a spell, putting them as creditors for what was owed until sustainable?

[the_doctor] 15/7/2011 10:08

'You are SO wrong Doc.!.'


ss, no offence, but I'd me more inclined to believe you if you hadnt been posting irrelevant links ALL the way down

if a news article doesnt either:
a) increase chances of new partners coming in
b) increase likelihood of partners investing more in marketing
c) materially increase awareness in CLN as a potential aid for dementia/AD
d) encourage regulators to look more favourably on AD neutraceuticals

Then it wont help. As I've posted before, it is ESSENTIAL that RGT secures several 100k more orders over the next 12months or so.
Nothing else matters.

[share_shark] 15/7/2011 09:58

You are SO wrong Doc.!.

[the_doctor] 15/7/2011 09:33

Most of this is irrelevant, do you not see ss?

RGT's future rests on existing and new partners buying/selling enough product.

[share_shark] 15/7/2011 08:30

Rice researchers announce Alzheimer's breakthrough
by Franz Osorio | July 14, 2011 2:26 pm



A recent finding from Rice University may make it easier to find signs of Alzheimer's.

The research, conducted by bioengineer Angel Mart, involves molecules that bond with fibrils, which form the plaque in the brains of Alzheimer's sufferers. This discovery could lead to medications that can help identify and treat the disease.

The findings are reported in the Journal of the American Chemical Society. Nathan Cook, one of the article's authors, originally started working with molecules intended to dissolve these fibrils, but his research eventually led him to this discovery of metallic molecules that attach to fibrils.

Cook wants to continue his research and find a way that fibril-dissolving and finding compounds can work together to treat Alzheimer's and similar diseases.

[share_shark] 15/7/2011 08:23

Chuckle.
Thank you Asmod and I will try and keep a tight reign on what I forward to him.
;-).

Seriously thank you and I agree with you comments on last findings.

SS.

[asmodeus] 15/7/2011 08:11

Dear Share_Shark. Am so delighted that your love for me, so long concealed, has at last been confessed! Tim's address is [e-mail]
I forwarded your relevant findings to him yesterday, but, from now on, will assume that you will do this Yourself, unless you tell me otherwise. He does appreciate being kept informed, but, please, only with really relevant items, such as the relaxation in approvals etc. - not just that more people are contracting Alz., etc
I imagine your two latest findings above would be appreciated.

[share_shark] 15/7/2011 07:55

There is going to be a huge amount of publicity over the next two weeks with regards to Alzheimers.

Asmod angel. Do you have Tims email addy please?. I must be getting old because I do not have it to hand. TIA.



Texas consortium to present on diagnostic blood test at international Alzheimer's conference
Kelley Shannon Special to the Standard-Times
San Angelo Standard Times
Posted July 14, 2011 at 7:06 p.m.
.





AUSTIN - A unique Texas research team delving into the causes and diagnosis of Alzheimer's disease has received renewed state funding and is about to play a prominent role at an international convention in France.

The Texas Alzheimer's Research Consortium will share its latest findings about a low-cost blood test to detect the disease during the International Convention on Alzheimer's disease starting this weekend.

[share_shark] 15/7/2011 07:16

Research breakthrough 'could lead to new Alzheimer's treatments'

Healthcare News
14/07/2011
New findings could allow researchers to better see and potentially eliminate amyloid fibrils in the brain.

[share_shark] 14/7/2011 18:46

RHPS tipnewsletter commenting tonight on various shares.



"The performance of Summit suggests that there is a real appetite for shares in the biotech sector. Natural resources are, for the time being at least, out of favour but biotech could be the next hot sector.

[share_shark] 14/7/2011 16:13

PET scans next step.

[share_shark] 14/7/2011 12:51

Angel......one for Tim ?.

Alzheimer's risk written in genes
Published on Thu, 14/07/2011, 02:20:56


|
New research from the US has uncovered evidence that damage to the brain that could contribute to the development of Alzheimer's disease begins developing from a young age in people who carry an unfortunate combination of genes.

It is known that genes play a strong role in the development of Alzheimer's disease, but so far, according to a study published in the May edition of the Journal of Neuroscience, "few gene variants have been identified that reliably contribute to that risk".

One of the few that have been identified is a common variant of the CLU gene, carried by 88 per cent of Caucasians, which "begins to damage your brain a full 50 years before people normally get Alzheimer's", according to a news release from the University of California, Los Angeles (UCLA).

The research team, led by Professor Paul Thompson, scanned the brains of 398 healthy adults ranging from 20 to 30 years of age, using a new type of magnetic resonance imaging (MRI) scan that maps the brain's connections, also known as 'white matter'.

They compared those carrying a C-allele variant of the CLU gene with those who had a different variant, the CLU T-allele, and found that there was already degeneration occurring in the white matter of those 20-somethings with the risk gene.

"For example, Alzheimer's has traditionally been considered a disease marked by neuronal cell loss and widespread grey-matter atrophy," Professor Thompson said. "But degeneration of myelin in white-matter fibre pathways is more and more being considered a key disease component and another possible pathway to the disease, and this discovery supports that."

Professor Thompson drew four main conclusions from the research.

"This risk gene damages your brain a full 50 years before people normally get Alzheimer's. The damage can be seen on an MRI scan, but there are no symptoms yet.

"[Secondly], it's now known what this mysterious gene does - namely, make your brain wiring vulnerable to attack by impairing the wiring before any senile plaques or tangles develop.

"Finally, knowing the role of this gene is useful in predicting a person's risk of the disease and in seeing if you can step in and protect the brain in the 50-year time window you have before the disease begins to develop."

"We know that many lifestyle factors, such as regular exercise and a healthful diet, may reduce the risk of cognitive decline, particularly in those genetically at risk for Alzheimer's, so this reminds us how important that is."

The professor said the brain could compensate for the changes observed in the study's young participants and that other factors, such as the normal neuron death that is associated with age, would most likely to contribute to the development of Alzheimer's disease.

"So it's unlikely we are seeing the earliest possible signs of Alzheimer's-associated brain changes in these young people," he said.

"It's more likely the reduced fibre integrity represents an early developmental vulnerability that may reduce brain resilience to later Alzheimer's disease pathology. In other words, its mechanism of action may not be part of the classic Alzheimer's pathways that lead to abnormal amyloid plaque and neurofibrillary tangle accumulation in the brain."

[share_shark] 14/7/2011 09:35

$2.9 million to study diseases such as Alzheimer's

[share_shark] 14/7/2011 09:28

Summ Angel. ;-)

Hope for millions of Alzheimer's sufferers as scientists make brain cells from human skin

[asmodeus] 14/7/2011 08:41

Have sent him above, also. BTW - which Company was it? Angelic Asmo.

[share_shark] 14/7/2011 08:11

You really are a ANGEL asmodeus and thank you.

Have you seen this ?.

POSITIVE RESULTS TO BE REPORTED AT INTERNATIONAL ALZHEIMER'S DISEASE CONFERENCE

Alzheimer's Association International Conference on Alzheimer's Disease 2011

16-21 July 2011

Paris, France



18/5/11

The Company has reportedly received much interest from prospective partners in their Alzheimer's research programme on the back of overall popularity of the OGA target from the wider pharmaceutical industry. We understand that at least two pharmaceutical companies are undergoing internal evaluation of the active compounds.

[asmodeus] 14/7/2011 08:09

Excellent find, S_S. I have forwarded it to Tim for you.

[share_shark] 14/7/2011 07:20

vised rules aim to speed new Alzheimer's drugs
By MARILYNN MARCHIONE , 07.12.11, 12:02 AM EDT

The government is making it easier to test new Alzheimer's drugs, hoping to speed progress toward new treatments for the mind-robbing disease.

One of every eight people 65 or older has Alzheimer's, the most common form of dementia. Current drugs only ease symptoms temporarily and don't slow its advance.

Many drugs have flopped in late-stage testing in recent years, including some that seemed to clear harmful plaque from addled brains.

Last year, the Food and Drug Administration put restrictions on who could be in experiments targeting this plaque. They agency said participants had to drop out if they developed signs of bleeding in the brain.

A panel of industry, nonprofit and academic researchers thought that would choke off promising research. They gathered evidence that such bleeding and other abnormalities seen on brain scans were fairly common and might even be a sign that a drug is working as intended.

That would mean it doesn't necessarily doom a treatment, said Dr. Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women's and Massachusetts General Hospitals. "It's not clear yet whether these are a sign of damage, but they may not be as concerning as we initially thought."

The FDA was persuaded, and adopted the panel's findings, which are being published online Tuesday in the journal Alzheimer's & Dementia.

The relaxed rules are a boon for companies like Pfizer Inc. and Johnson & Johnson subsidiary Janssen Alzheimer Immunotherapy, which are testing an experimental drug called bapineuzumab (bap-ih-NUZE-uh-mab) in thousands of patients now. Eli Lilly & Co. also has an Alzheimer's drug in late-stage tests. Those companies took part in the panel that came up with the new rules.

They will be discussed next week at an international Alzheimer's Association conference in Paris.

[shoggoth] 28/3/2011 23:57

My god, I remember when this was floated, and thought about investing. It has been a one-way ticket for 10 years. 10 years!

[stenick] 11/3/2011 19:05

I got the ADI shares and now the warrants are listed aswell,well I don't mean to be picky but they could have just given me a load of cash instead...LOL.